Christian Harding
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$12.1MFederal grants as PI15 awards
3Patents grantedLatest Mar 17, 2026
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
15 awards · $12.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 12, 2026 | NIH | SBIR Phase II A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | $999K | VAXNEWMO, LLC |
| Jul 16, 2026 | NIH | STTR Phase II A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | $1.0M | VAXNEWMO, LLC |
| Sep 9, 2025 | NIH | STTR Phase II A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | $1000K | VAXNEWMO, LLC |
| Aug 25, 2025 | NIH | SBIR Phase II A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | $1.0M | VAXNEWMO, LLC |
| Jun 20, 2025 | NIH | SBIR Phase II Development of a Group B Streptococcus bioconjugate vaccine | $996K | VAXNEWMO, LLC |
| Aug 20, 2024 | NIH | STTR Phase II A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | $994K | VAXNEWMO, LLC |
| May 15, 2024 | NIH | SBIR Phase II Development of a Group B Streptococcus bioconjugate vaccine | $996K | VAXNEWMO, LLC |
| Jun 16, 2023 | NIH | STTR Phase II A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | $298K | VAXNEWMO, LLC |
| Jun 14, 2023 | NIH | SBIR Phase II Development of a Group B Streptococcus bioconjugate vaccine | $1.0M | VAXNEWMO, LLC |
| Dec 8, 2022 | NIH | STTR Phase I A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | $293K | VAXNEWMO, LLC |
| Jul 6, 2022 | NIH | STTR Phase II A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | $299K | VAXNEWMO, LLC |
| Jan 10, 2022 | NIH | SBIR Phase II Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines | $985K | VAXNEWMO, LLC |
| Dec 27, 2021 | NIH | STTR Phase I A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | $300K | VAXNEWMO, LLC |
| Jan 28, 2021 | NIH | SBIR Phase II Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines | $993K | VAXNEWMO, LLC |
| Feb 4, 2020 | NIH | SBIR Phase II Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines | $931K | VAXNEWMO, LLC |
4 patents as inventor
- US 11932670VAXNEWMO, LLCMar 19, 2024
- US 12350342VAXNEWMO, LLCJul 8, 2025
- US 12577280VAXNEWMO, LLCMar 17, 2026
- US VAXNEWMO, LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#39
Awards as PI#46
Patents#63
Companies
- VAXNEWMO, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.